Clinical Trial Update: Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas [Phase 2]

View source ↗

Summary

The Phase 2 exploratory trial of farletuzumab for resectable, non-functioning pituitary adenomas has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pituitary Adenoma

Drugs mentioned

• Farletuzumab (farletuzumab)

Snippet

Sponsor: Morphotek | Conditions: Resectable, Non-functioning Pituitary Adenoma | Phase 2 | Status: WITHDRAWN